- Monday, 23 April 2012
- AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout AstraZeneca and Ardea Biosciences, Inc. (Ardea) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea’s clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.
- Monday, 16 April 2012
- Conformetrix and AstraZeneca sign collaborative agreement Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.
- Monday, 2 April 2012
- AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio AstraZeneca and Amgen today announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).